deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03025789

Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage

An Open-label Study Assessing Effectiveness, Safety and Compliance With Fexinidazole in Patients With Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage

Sponsor: Drugs for Neglected Diseases

Conditions Sleeping Sickness Trypanosomiasis, African Trypanosomiasis; Gambian
Interventions Fexinidazole
Updated 14 times since 2017 Last updated: Dec 20, 2024 Started: Nov 10, 2016 Primary completion: Feb 1, 2021 Completion: Feb 1, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Sleeping Sickness and Trypanosomiasis, African, this trial is completed. The trial is conducted by Drugs for Neglected Diseases and has accumulated 14 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Jan 2020 · 7 months · monthly snapshot~Jan 2020 – ~Nov 2020 · 10 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshot~Nov 2021 – ~Aug 2023 · 21 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Feb 2025 — Sep 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Feb 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 9 earlier versions

  1. Nov 2021 — Aug 2023 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Jan 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Jan 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  5. Jun 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  6. Jun 2018 — Jun 2019 [monthly]

    Recruiting PHASE3

  7. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

  8. Sep 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  9. Feb 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

    First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Drugs for Neglected Diseases
  • Sanofi
Data source: Drugs for Neglected Diseases

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations